Reference Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Filter rows:

Showing 1 to 1 of 1 entries

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
Olverembatinib	Olverembatinib	26	3

Showing 1 to 1 of 1 entries

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Olverembatinib		HQP 1351\|HQP-1351\|GZD824 dimesylate\|GZD824\|HQP1351	ABL1 Inhibitor 8 FGFR1 Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR-alpha Inhibitor 10	Olverembatinib (HQP1351) is a third-generation BCR-ABL inhibitor and multikinase inhibitor that inhibits KIT, ABL1, FGFR1, FLT3, and PDGFRA (PMID: 32247263), which potentially induces apoptosis, and inhibits tumor cell growth, migration, and invasion (PMID: 31673329).

Showing 1 to 1 of 1 entries

Filter rows:

Showing 1 to 2 of 2 entries

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
FLT3	E654D	missense	unknown	FLT3 E654D lies within the protein kinase domain of the Flt3 protein (UniProt.org). E654D has been identified in the scientific literature (PMID: 32247263), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Dec 2024).
FLT3	Y842R	missense	unknown	FLT3 Y842R lies within the protein kinase domain of the Flt3 protein (UniProt.org). Y842R has been identified in the scientific literature (PMID: 32247263), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Dec 2024).

Showing 1 to 2 of 2 entries

Filter rows:

Showing 1 to 18 of 18 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Olverembatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Olverembatinib (HQP1351) reduced Flt3 and Stat5 phosphorylation, induced cell cycle arrest and apoptosis, and inhibited growth of acute myeloid leukemia cells harboring FLT3-ITD in culture, and suppressed tumor growth, decreased Flt3 activation, and induced apoptosis in cell line xenograft models (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 F691I	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Olverembatinib (HQP1351) reduced Flt3 and Stat5 phosphorylation and inhibited growth of transformed cells expressing FLT3-ITD and FLT3 F691I in culture, and suppressed tumor growth, decreased Flt3 activation, and induced apoptosis in cell line xenograft models (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 E654D	acute myeloid leukemia	predicted - sensitive	Olverembatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) reduced Flt3 and Stat5 activation and inhibited growth of patient-derived acute myeloid leukemia cells harboring FLT3-ITD and FLT3 E654D in culture (PMID: 32247263).	32247263
FLT3 D835H	hematologic cancer	predicted - sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 D835H demonstrated decreased proliferation in response to Olverembatinib (HQP1351) in culture, but were less sensitive to treatment than cells expressing other FLT3 kinase domain mutations (PMID: 32247263).	32247263
FLT3 D835V	hematologic cancer	predicted - sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 D835V demonstrated decreased proliferation in response to Olverembatinib (HQP1351) in culture, but were less sensitive to treatment than cells expressing other FLT3 kinase domain mutations (PMID: 32247263).	32247263
FLT3 D835Y	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3 D835Y in culture (PMID: 32247263).	32247263
FLT3 exon 14 ins	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3-ITD in culture (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 D835A	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3-ITD and FLT3 D835A in culture (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 D835G	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3-ITD and FLT3 D835G in culture (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 D835I	hematologic cancer	predicted - sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835I demonstrated decreased proliferation in response to Olverembatinib (HQP1351) in culture, but were less sensitive to treatment than cells co-expressing FLT3-ITD with other FLT3 kinase domain mutations (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 D835N	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3-ITD and FLT3 D835N in culture (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 D835V	hematologic cancer	predicted - sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835V demonstrated decreased proliferation in response to Olverembatinib (HQP1351) in culture, but were less sensitive to treatment than cells co-expressing FLT3-ITD with other FLT3 kinase domain mutations (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 D835Y	hematologic cancer	predicted - sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y demonstrated decreased proliferation in response to Olverembatinib (HQP1351) in culture, but were less sensitive to treatment than cells co-expressing FLT3-ITD with other FLT3 kinase domain mutations (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 G697R	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3-ITD and FLT3 G697R in culture (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 N676D	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3-ITD and FLT3 N676D in culture (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 Y842H	hematologic cancer	sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3-ITD and FLT3 Y842H in culture (PMID: 32247263).	32247263
FLT3 R834Q	hematologic cancer	predicted - sensitive	Olverembatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 R834Q demonstrated decreased proliferation in response to Olverembatinib (HQP1351) in culture, but were less sensitive to treatment than cells expressing other FLT3 kinase domain mutations (PMID: 32247263).	32247263
FLT3 exon 14 ins FLT3 Y842R	hematologic cancer	sensitive	Olverembatinib	Preclinical	Actionable	In a preclinical study, Olverembatinib (HQP1351) inhibited growth of transformed cells expressing FLT3-ITD and FLT3 Y842R in culture (PMID: 32247263).	32247263

Showing 1 to 18 of 18 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting